Global healthcare startup Sky Labs (CEO Byung-hwan Lee) received 22.5 billion won in Series B funding from Atinum Investment, Moru Asset Management, Soo Investment Capital, KB Investment, Korea Investment Partners, and LB Investment, bringing the cumulative investment amount. It was revealed that this amounted to approximately 34.3 billion won.
The company explained that the company’s technological competitiveness and business capabilities were highly evaluated as many large domestic investment companies participated in the investment. Skylabs has also received investment from TBT and Chong Kun Dang.
Skylabs’ AI-based heart monitoring platform, CART-I, consists of a ring-shaped wearable medical device, a user app, and a web platform for doctors so that patients with atrial fibrillation can be monitored outside the hospital. It automatically observes blood flow in the finger through a photoplethysmography sensor (PPG) and measures irregular pulse waves. The measured data is sent to the cloud to detect and analyze atrial fibrillation through AI analysis, and the results are delivered to the user app and doctor-only web.
In particular, we have proven the accuracy of atrial fibrillation detection by conducting clinical research with leading domestic and foreign medical institutions during product development. Through this, it obtained CE-MDD (Medical Devices Directive) from the Korean Ministry of Food and Drug Safety as well as European medical device product approval. We are the only Korean company to be invited to the European Society of Cardiology (ESC) and have been recognized for our technology and competitiveness in the global market, including taking first place in the digital health category for two consecutive years and being selected as a Technology Pioneer at the 2019 World Economic Forum. there is.
Through this investment, we will expand global clinical research in the UK, Netherlands, Germany, and the US, and strengthen global marketing, including branches in the US and Europe, to target overseas healthcare markets. In addition, we plan to license and launch various chronic disease monitoring functions and recruit excellent human resources.
Kim Jin-yong, director of KB Investment and a former internal medicine specialist who led this investment, said, “CartOne is capable of sophisticated analysis of heart rhythm beyond simple heart rate and heart rate variability, enabling continuous monitoring of important vital signs such as blood pressure and oxygen saturation and medical-level signals. “We believe it is the most advanced type of wearable medical device capable of analysis,” he said. “Continuous and precise monitoring outside the hospital for the continuous management of patients with chronic diseases is an important element of personalized future medical care, and we believe that Cartone will be able to implement this.” “I do it,” he said.
SkyLabs CEO Byeong-Hwan Lee said, “This investment is a confirmation of SkyLabs’ technical capabilities and clinical research capabilities in AI, software, and hardware, as well as the feasibility and scalability of the Cart platform, and is a high-value demonstration of our business capabilities that are expanding globally. “As a result of the evaluation,” he said, “using this investment as a stepping stone, we will fundamentally change the healthcare market for patients with chronic diseases outside hospitals around the world at a faster rate than the current growth rate.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ n